Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.58 |
| ▸ | MMP13 | P45452 | 4/20 | 0.58 |
| ▸ | MMP8 | P22894 | 4/20 | 0.52 |
| ▸ | MMP3 | P08254 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240347 | 0.91 | MMP1 (0.59) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL6237846 | 0.90 | MMP1 (0.70) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL6238225 | 0.90 | MMP1 (0.70) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL7764274 | 0.83 | MMP1 (0.53) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL6240405 | 0.82 | MMP1 (0.56) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL6383423 | 0.82 | MMP1 (0.59) | MMP1ADAM17MMP13MMP8MMP3 | |
| SCHEMBL6241058 | 0.81 | MMP1 (0.71) | MMP1ADAM17MMP13 | |
| SCHEMBL6237788 | 0.81 | MMP1 (0.71) | MMP1ADAM17MMP13 | |
| SCHEMBL6240997 | 0.81 | MMP1 (0.63) | MMP1ADAM17MMP13MMP3MMP9 | |
| SCHEMBL27573429 | 0.81 | ADAM17 (0.59) | MMP1ADAM17MMP13MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | MMP1 15/4885ADAM17 19/4885MMP13 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.